MSN's Molulow 200 mg caps for Covid

Hyderabad: City-based MSN Group, is all set to launch the generic molnupiravir 200 mg capsules for treating Covid-19 under the brand name Molulow.

Molnupiravir is an oral Covid-19 antiviral medicine indicated for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

MSN Group said: "After enabling affordable access to a series of critical Covid-19 drugs such as Oselow, Favilow, Baridoz, and Posaone, at crucial junctures, we at MSN Group are glad to be launching Molulow, which can be a game-changer in our nation's fight against the pandemic. Being an orally administered option, we are confident that this medicine will increase treatment compliance and bring relief to the Covid-19 patients."

Molulow, which received Emergency Use Approval (EUA) approval from DCGI, comes as a pack of 4x10 capsule strips with each capsule of 200 mg strength. A dosage regimen of 800 mg for five days (four capsules of 200 mg twice a day) is recommended in addition to standard medical care. Molulow is being manufactured at MSN Group's USFDA and MHRA accredited facility here. The drug, to be dispensed upon a medical prescription, will be made available at all retail pharmacies soon at the most affordable price.

MSN Group, which has successfully conducted clinical trials of molnupiravir in India and presented its findings to DCGI, has recently received the licence from the Medicines Patent Pool (MPP) for manufacturing and distribution of molnupiravir for treating Covid-19. This agreement will also help MSN Group in enabling access to molnupiravir in over 100 low-and middle-income countries (LMICs) following regulatory approvals of respective countries.